Anixa Biosciences(US:ANIX) Prnewswire·2026-02-23 13:55Core Insights - Anixa Biosciences, Inc. is focused on cancer treatment and prevention, with a key highlight being Dr. Jose Conejo-Garcia's keynote speech at the SCTR 2026 Retreat, discussing the company's CAR-T technology and ongoing clinical trials [1][2]. Group 1: Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a therapeutic portfolio that includes liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center [5]. - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor instead of an antibody fragment [5]. - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers, focusing on immunizing against specific proteins expressed in certain cancer forms [5]. Group 2: Clinical Trials and Research - The ongoing Phase 1 clinical trial of lira-cel targets adult women with recurrent ovarian cancer who have progressed after at least two prior therapies, utilizing the FSHR-mediated CAR-T therapy [4]. - Dr. Conejo-Garcia's presentation at the SCTR 2026 Retreat will cover the advancements and findings from the ongoing clinical trial of lira-cel [2]. Group 3: Industry Collaboration - The SCTR 2026 Retreat aims to foster collaboration among pioneers in research, clinical care, and industry, showcasing innovations in advanced cell therapy, immune therapy, and oncology [3].